<DOC>
	<DOCNO>NCT01483846</DOCNO>
	<brief_summary>This Phase 1b study involve multiple oral dos AV-101 healthy male female subject . The safety , pharmacokinetics , antihyperalgesic effect AV-101 capsaicin-induced hyperalgesia assess .</brief_summary>
	<brief_title>Safety , Tolerability Pharmacokinetics Multiple Doses AV-101 Healthy Volunteers</brief_title>
	<detailed_description>Healthy subject randomize three dose cohort ( 360 , 1,080 , 1,440 mg ) receive daily oral dos AV-101 14 consecutive day . Each cohort 12 subject active drug 4 subject placebo . Safety , PK , antihyperalgesic effect treatment AV-101 assess . At screen visit Day -28 Day -7 randomization , 250 Î¼g capsaicin intradermally deliver volar aspect one forearm . Subjects must report pain score least 4 10 qualify study . On Day 1 Day 14 follow data collect : ( 1 ) neurosensory test ( thermal sensation , thermal pain , touch , mechanical pain ) forearm ; ( 2 ) neurocognitive evaluation ; ( 3 ) 12-lead electrocardiogram , blood pressure , heart rate , respiratory rate , temperature . PK sample collect Days 1 , 2 , 14 , 15 . The capsaicin-induced pain assess screening , Day 1 , Day 14 . An intradermal injection capsaicin forearm Day 1 Day 14 follow efficacy measure . On Day 1 administration first dose , subject give paper diary record daily self-administration dose , concomitant medication , adverse event 14-day treatment period .</detailed_description>
	<mesh_term>Neuralgia</mesh_term>
	<mesh_term>Capsaicin</mesh_term>
	<criteria>A subject eligible participation full study follow criterion meet : 1 . Be male female , age 21 60 year inclusive , healthy , able willing provide write informed consent participate study . 2 . Be able read speak English sufficiently understand follow study instruction , include completion pain intensity rating scale . 3 . For male , must use birth control ( condom ) prevent father child ; female must nonlactating , pregnant , use reliable contraception method ( e.g. , abstinence , intrauterine device , hormonal birth control , double barrier method [ male condom , female condom , diaphragm plus spermicidal agent contraceptive foam , jelly , cream ] ) . 4 . Have visual analog pain score least 4 10 screening . Subjects exclude study one follow condition apply : 1 . History peripheral neuropathy chronic pain condition . 2 . History significant hepatic , ophthalmic ( include previous current cataract ) , cardiovascular , renal , gastrointestinal , hematological , neurological , endocrine ( include diabetes ) , metabolic , pulmonary , psychiatric disease . Significance determine principal investigator . 3 . Clinically significant abnormality screen electrocardiogram judgment investigator would place subject risk cardiac adverse event result capsaicin injection administration AV101 . 4 . Cognitive psychiatric disorder may diminish compliance study procedure . 5 . Dermatopathology , skin hypersensitivity , skin lesion area capsaicin application . 6 . Allergy capsaicin study medication . 7 . Current tobacco use . 8 . Use chemotherapy agent history cancer , resolve skin cancer , within 5 year screen visit . 9 . History drug alcohol abuse within 1 year screening . 10 . History AIDS , test HIV positive , use antiretroviral therapy . 11 . Use , within 4 week study drug dosing , investigational drug , epidural intrathecal agent , corticosteroid , topical anesthetic , topical analgesic , central alpha agent ( e.g. , clonidine ) , alpha blocker ( e.g. , praxosin , terazosin ) , beta blocker , calcium channel blocker , ACE inhibitor . 12 . Use within 7 day entire period study drug dose longacting nonsteroidal antiinflammatory drug ( NSAIDs ) piroxicam naproxen . 13 . Use within 36 hour entire period study drug dose NSAIDs , aspirin , acetaminophen , antihistamine , sympathomimetics ( e.g. , pseudoephedrine ephedrine ) , caffeine alcohol .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>Neuropathic Pain</keyword>
	<keyword>Capsaicin Induced Pain</keyword>
</DOC>